What is the Challenge?

25% of people will get cancer during their life, and half of them will have solid tumors. The treatments are making progress every year and T-cell treatment is an individualized treatment. The challenge is to get the right T-cells and expand them to substantial amount with high quality for injecting back in the patient. CuraCell has a strong technology in this field and aim to start a clinical trial next year focusing on breast cancer and prostate cancer.

What is the Solution?

CuraCell is producing a more effective cancer cure. They are building on a previously existing technology that uses the patients’ own immune system to fight cancer cells. After the primary tumor is removed through surgery, CuraCell’s treatment isolates and identifies special T cells. These T cells are called Tumor Infiltrating Lymphocytes (TIL), and they are specifically focused on treating tumors. Next, CuraCell’s process grows more of them and makes them individually more effective. When enough cancer-killing T cells have been produced, they are then reintroduced into the patient’s body. They are then able to recognize and kill the tumor cells that have transferred elsewhere in the patient’s body, which are usually very dangerous.

In its previous version, this type of T cell therapy has been tested on over 200 patients worldwide. The success rate was good, and Curacell has since developed the process to make it even more effective. Their ambition is to achieve a success rate of over 50%, a number high above any other cancer cure on the market.